Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$14.41M-$14.41MN/M vs Q3 2021 EPS Diluted-$6.41-$6.41N/M vs Q3 2021 Operating Income-$14,488,064N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end